A Phase II Trial Evaluating the Feasibility of Adding Bevacizumab to Standard Osteosarcoma Therapy

Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in pa...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Int J Cancer
Main Authors: Navid, Fariba, Santana, Victor M., Neel, Michael, McCarville, M. Beth, Shulkin, Barry L., Wu, Jianrong, Billups, Catherine A., Mao, Shenghua, Daryani, Vinay M., Stewart, Clinton F., Kunkel, Michelle, Smith, Wendene, Ward, Deborah, Pappo, Alberto S., Bahrami, Armita, Loeb, David M., Willert, Jennifer Reikes, Rao, Bhaskar N., Daw, Najat C.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5812455/
https://ncbi.nlm.nih.gov/pubmed/28631382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30841
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker